These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 9564614

  • 21. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration.
    Gelowitz DL, Paterson IA.
    Pharmacol Biochem Behav; 1999 Feb; 62(2):255-62. PubMed ID: 9972692
    [Abstract] [Full Text] [Related]

  • 22. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D, Szökõ E, Magyar K.
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [Abstract] [Full Text] [Related]

  • 23. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM, Mohanakumar KP, Murphy DL, Chiueh CC.
    Ann N Y Acad Sci; 1994 Nov 17; 738():214-21. PubMed ID: 7832430
    [Abstract] [Full Text] [Related]

  • 24. Pharmacological aspects of (-)-deprenyl.
    Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szöko E.
    Curr Med Chem; 2004 Aug 17; 11(15):2017-31. PubMed ID: 15279565
    [Abstract] [Full Text] [Related]

  • 25. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J.
    J Neural Transm Suppl; 1993 Aug 17; 40():69-91. PubMed ID: 8294902
    [Abstract] [Full Text] [Related]

  • 26. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R, Ebadi M, Pfeiffer RF.
    Neurosci Lett; 1995 Nov 17; 200(2):77-80. PubMed ID: 8614567
    [Abstract] [Full Text] [Related]

  • 27. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP.
    Neurochem Int; 2006 Jul 17; 49(1):28-40. PubMed ID: 16490285
    [Abstract] [Full Text] [Related]

  • 28. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.
    Sanz E, Romera M, Bellik L, Marco JI, Unzeta M.
    Med Sci Monit; 2004 Dec 17; 10(12):BR477-84. PubMed ID: 15567979
    [Abstract] [Full Text] [Related]

  • 29. A review of the pharmacology of selegiline.
    Heinonen EH, Lammintausta R.
    Acta Neurol Scand Suppl; 1991 Dec 17; 136():44-59. PubMed ID: 1686954
    [Abstract] [Full Text] [Related]

  • 30. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I.
    Neuropsychopharmacol Hung; 2008 Mar 17; 10(1):15-22. PubMed ID: 18771016
    [Abstract] [Full Text] [Related]

  • 31. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J.
    J Am Geriatr Soc; 1992 Aug 17; 40(8):839-47. PubMed ID: 1634730
    [Abstract] [Full Text] [Related]

  • 32. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
    Miklya I.
    Neuropsychopharmacol Hung; 2009 Dec 17; 11(4):217-25. PubMed ID: 20150659
    [Abstract] [Full Text] [Related]

  • 33. The distribution of orally administered (-)-deprenyl-propynyl-14C and (-)-deprenyl-phenyl-3H in rat brain.
    Magyar K, Lengyel J, Szatmári I, Gaál J.
    Prog Brain Res; 1995 Dec 17; 106():143-53. PubMed ID: 8584650
    [Abstract] [Full Text] [Related]

  • 34. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Jenner P.
    Neurology; 2004 Oct 12; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
    [No Abstract] [Full Text] [Related]

  • 35. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells.
    Suuronen T, Kolehmainen P, Salminen A.
    Biochem Pharmacol; 2000 Jun 15; 59(12):1589-95. PubMed ID: 10799657
    [Abstract] [Full Text] [Related]

  • 36. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F.
    Br J Pharmacol; 1987 Feb 15; 90(2):335-45. PubMed ID: 3103805
    [Abstract] [Full Text] [Related]

  • 37. (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes.
    Takahata K, Shimazu S, Yoneda F.
    Pharmacol Res; 2004 Mar 15; 49(3):253-8. PubMed ID: 14726221
    [Abstract] [Full Text] [Related]

  • 38. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A, McGeer PL.
    Exp Neurol; 2000 Dec 15; 166(2):458-64. PubMed ID: 11085911
    [Abstract] [Full Text] [Related]

  • 39. Behaviour of (-)-deprenyl and its analogues.
    Magyar K.
    J Neural Transm Suppl; 1994 Dec 15; 41():167-75. PubMed ID: 7931223
    [Abstract] [Full Text] [Related]

  • 40. The effect of low oral doses of (-)-deprenyl and its metabolites on DSP-4 toxicity.
    Haberle D, Szökö E, Halász AS, Magyar K.
    J Neural Transm (Vienna); 2001 Dec 15; 108(11):1239-47. PubMed ID: 11768624
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.